A detailed history of Bank Of America Corp transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 583,925 shares of ALLO stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
583,925
Previous 432,703 34.95%
Holding current value
$1.2 Million
Previous $1.01 Million 62.1%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.08 - $3.5 $314,541 - $529,277
151,222 Added 34.95%
583,925 $1.63 Million
Q2 2024

Aug 14, 2024

BUY
$2.23 - $4.38 $63,155 - $124,045
28,321 Added 7.0%
432,703 $1.01 Million
Q1 2024

May 15, 2024

BUY
$2.92 - $5.63 $214,602 - $413,771
73,494 Added 22.21%
404,382 $1.81 Million
Q4 2023

Feb 14, 2024

SELL
$2.28 - $3.5 $876,844 - $1.35 Million
-384,581 Reduced 53.75%
330,888 $1.06 Million
Q2 2023

Aug 14, 2023

SELL
$4.53 - $6.74 $1.43 Million - $2.13 Million
-316,195 Reduced 30.65%
715,469 $3.56 Million
Q1 2023

May 12, 2023

BUY
$4.92 - $8.21 $822,555 - $1.37 Million
167,186 Added 19.34%
1,031,664 $5.1 Million
Q4 2022

Feb 10, 2023

BUY
$5.62 - $11.11 $2.81 Million - $5.56 Million
500,817 Added 137.72%
864,478 $5.44 Million
Q3 2022

Nov 14, 2022

BUY
$10.32 - $17.28 $987,304 - $1.65 Million
95,669 Added 35.7%
363,661 $3.93 Million
Q2 2022

Aug 12, 2022

SELL
$6.78 - $12.28 $2.11 Million - $3.83 Million
-311,934 Reduced 53.79%
267,992 $3.06 Million
Q1 2022

May 16, 2022

BUY
$7.65 - $15.29 $2.37 Million - $4.74 Million
310,292 Added 115.08%
579,926 $5.28 Million
Q4 2021

Feb 08, 2022

BUY
$13.13 - $24.52 $2.78 Million - $5.19 Million
211,768 Added 365.96%
269,634 $4.02 Million
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $2.21 Million - $2.91 Million
-105,235 Reduced 64.52%
57,866 $1.49 Million
Q2 2021

Sep 13, 2021

BUY
$23.49 - $35.8 $3.83 Million - $5.84 Million
163,101 New
163,101 $4.25 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $296M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.